SCHEMBL20161943

SCHEMBL20161943

COC(=O)c1cc(Cc2cnc(N)s2)c(C)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.47
JAK3 P52333 1/20 0.47
TSHR P16473 2/20 0.43
POLB P06746 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GAA P10253 2/20 0.41
TXK P42681 1/20 0.41
ITK Q08881 1/20 0.41
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
MAPT P10636 2/20 0.38
HSD17B10 Q99714 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
BACE1 P56817 1/20 0.35
DPP4 P27487 2/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932953 1.00 BTK (0.47) BTKJAK3TSHRPOLBSMN1; SMN2
SCHEMBL20161892 0.89 BTK (0.45) BTKJAK3TSHRPOLBSMN1; SMN2
SCHEMBL20143678 0.77 BTK (0.56) BTKJAK3POLBTXKITK
SCHEMBL5655948 0.77 JAK3 (0.48) BTKJAK3TXKITK
SCHEMBL29932927 0.76 TSHR (0.48) TSHRPOLBSMN1; SMN2GAAKDM4E
SCHEMBL29932899 0.76 TSHR (0.48) TSHRPOLBSMN1; SMN2GAAKDM4E
SCHEMBL15396245 0.70 GAA (0.45) POLBSMN1; SMN2GAAKDM4EALDH1A1
SCHEMBL27997768 0.70 POLB (0.65) TSHRPOLBSMN1; SMN2GAAKDM4E
SCHEMBL11385067 0.69 GAA (0.63) TSHRPOLBSMN1; SMN2GAAKDM4E
SCHEMBL29933029 0.69 POLB (0.56) TSHRPOLBSMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
CN-110099684-B Compounds and methods for modulating interleukin-2-inducible T cell kinase 科尔沃斯制药股份有限公司 2022-11-11 CN disclosed
EP-3534899-B1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS INC (US) 2022-06-01 EP disclosed
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
WO-2018089261-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase IL2, NFATC1, IL2RA BTK 398/4885JAK3 341/4885TSHR 4016/4885
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA BTK 398/4885JAK3 341/4885TSHR 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.